FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904992459> ?p ?o ?g. }

• W2904992459 endingPage "889" @default.
• W2904992459 startingPage "881" @default.
• W2904992459 abstract "Background: The efficacy/safety of device-supported versus routine titration with Gla-300 in type 2 diabetes (T2DM) was evaluated. Method: AUTOMATIX was a 16-week, randomized, open-label, parallel-group, multicenter, noninferiority trial in insulin-treated or insulin-naïve people with T2DM. The fasting self-monitored plasma glucose (FSMPG) target was 90-130 mg/dL (5.0-7.2 mmol/L). Primary endpoint: proportion of participants achieving target FSMPG at week 16 without severe hypoglycemia. Secondary endpoints included: proportion reaching FSMPG target without confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemia; time to first achieve FSMPG target; mean FSMPG and HbA1c change (baseline to week 16). Safety endpoints included hypoglycemia and adverse events. Patient-reported outcomes (PROs) were also assessed. Results: Participants were randomized to device-supported (n = 75) or routine titration (n = 76); 17 participants in the device-supported group discontinued device use. Noninferiority was achieved for the primary endpoint (device-supported: 45.9%, routine: 36.8%; weighted difference: 9.04 [95% CI: −6.75, 24.83]), but not superiority ( P = .262). The proportion reaching FSMPG target range without confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemia was 34.3% vs 14.5%, respectively. The time at which 50% of the participants achieved the FSMPG target was less in the device-supported than routine titration arm (10 vs 13 weeks). Least squares mean HbA1c reduction, safety profiles, and PROs were similar in both arms. Mean “ease of use” score for the device, assessed by healthcare professionals and participants on a scale of 1-7, was ≥6. Conclusions: Device-supported self-titration had a good safety/efficacy profile, and was noninferior to routine titration and well accepted by diabetes specialists and patients." @default.
• W2904992459 created "2018-12-22" @default.
• W2904992459 creator A5020362616 @default.
• W2904992459 creator A5022459640 @default.
• W2904992459 creator A5036743289 @default.
• W2904992459 creator A5044894349 @default.
• W2904992459 creator A5047374640 @default.
• W2904992459 creator A5064086127 @default.
• W2904992459 creator A5078488183 @default.
• W2904992459 creator A5084593004 @default.
• W2904992459 creator A5090556361 @default.
• W2904992459 date "2019-01-15" @default.
• W2904992459 modified "2023-10-14" @default.
• W2904992459 title "A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes" @default.
• W2904992459 cites W1556195576 @default.
• W2904992459 cites W1813950028 @default.
• W2904992459 cites W1973030309 @default.
• W2904992459 cites W1974104194 @default.
• W2904992459 cites W1974223288 @default.
• W2904992459 cites W2007221722 @default.
• W2904992459 cites W2051083543 @default.
• W2904992459 cites W2056930506 @default.
• W2904992459 cites W2068300533 @default.
• W2904992459 cites W2086797813 @default.
• W2904992459 cites W2091252422 @default.
• W2904992459 cites W2101039355 @default.
• W2904992459 cites W2105744242 @default.
• W2904992459 cites W2121241046 @default.
• W2904992459 cites W2123946565 @default.
• W2904992459 cites W2152049006 @default.
• W2904992459 cites W2155568871 @default.
• W2904992459 cites W2168199710 @default.
• W2904992459 cites W2171294019 @default.
• W2904992459 cites W2190511217 @default.
• W2904992459 cites W2270439225 @default.
• W2904992459 cites W2529901556 @default.
• W2904992459 cites W2531173558 @default.
• W2904992459 cites W75467215 @default.
• W2904992459 doi "https://doi.org/10.1177/1932296818821706" @default.
• W2904992459 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6955447" @default.
• W2904992459 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646755" @default.
• W2904992459 hasPublicationYear "2019" @default.
• W2904992459 type Work @default.
• W2904992459 sameAs 2904992459 @default.
• W2904992459 citedByCount "20" @default.
• W2904992459 countsByYear W29049924592019 @default.
• W2904992459 countsByYear W29049924592020 @default.
• W2904992459 countsByYear W29049924592021 @default.
• W2904992459 countsByYear W29049924592022 @default.
• W2904992459 countsByYear W29049924592023 @default.
• W2904992459 crossrefType "journal-article" @default.
• W2904992459 hasAuthorship W2904992459A5020362616 @default.
• W2904992459 hasAuthorship W2904992459A5022459640 @default.
• W2904992459 hasAuthorship W2904992459A5036743289 @default.
• W2904992459 hasAuthorship W2904992459A5044894349 @default.
• W2904992459 hasAuthorship W2904992459A5047374640 @default.
• W2904992459 hasAuthorship W2904992459A5064086127 @default.
• W2904992459 hasAuthorship W2904992459A5078488183 @default.
• W2904992459 hasAuthorship W2904992459A5084593004 @default.
• W2904992459 hasAuthorship W2904992459A5090556361 @default.
• W2904992459 hasBestOaLocation W29049924591 @default.
• W2904992459 hasConcept C126322002 @default.
• W2904992459 hasConcept C134018914 @default.
• W2904992459 hasConcept C168563851 @default.
• W2904992459 hasConcept C197934379 @default.
• W2904992459 hasConcept C203092338 @default.
• W2904992459 hasConcept C2777180221 @default.
• W2904992459 hasConcept C2779306644 @default.
• W2904992459 hasConcept C2779920387 @default.
• W2904992459 hasConcept C2780473172 @default.
• W2904992459 hasConcept C2780668416 @default.
• W2904992459 hasConcept C2908918659 @default.
• W2904992459 hasConcept C2986379492 @default.
• W2904992459 hasConcept C555293320 @default.
• W2904992459 hasConcept C71924100 @default.
• W2904992459 hasConceptScore W2904992459C126322002 @default.
• W2904992459 hasConceptScore W2904992459C134018914 @default.
• W2904992459 hasConceptScore W2904992459C168563851 @default.
• W2904992459 hasConceptScore W2904992459C197934379 @default.
• W2904992459 hasConceptScore W2904992459C203092338 @default.
• W2904992459 hasConceptScore W2904992459C2777180221 @default.
• W2904992459 hasConceptScore W2904992459C2779306644 @default.
• W2904992459 hasConceptScore W2904992459C2779920387 @default.
• W2904992459 hasConceptScore W2904992459C2780473172 @default.
• W2904992459 hasConceptScore W2904992459C2780668416 @default.
• W2904992459 hasConceptScore W2904992459C2908918659 @default.
• W2904992459 hasConceptScore W2904992459C2986379492 @default.
• W2904992459 hasConceptScore W2904992459C555293320 @default.
• W2904992459 hasConceptScore W2904992459C71924100 @default.
• W2904992459 hasIssue "5" @default.
• W2904992459 hasLocation W29049924591 @default.
• W2904992459 hasLocation W29049924592 @default.
• W2904992459 hasLocation W29049924593 @default.
• W2904992459 hasLocation W29049924594 @default.
• W2904992459 hasLocation W29049924595 @default.
• W2904992459 hasLocation W29049924596 @default.
• W2904992459 hasLocation W29049924597 @default.
• W2904992459 hasOpenAccess W2904992459 @default.

• next